Our Focus on Immuno-Oncology
In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.
The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.
NEWS RELEASE
A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist)
In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…
EVENT
SMC Laboratories to Participate in Biotechgate Digital Partnering
SMC Laboratories will participate in the international online partnering event“Biotechgate Digital Partnering”…
Stem Cell Res Ther.
MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin αV-mediated lung fibrosis ( doi: 10.1186/s13287-025-04559-0.)
CDAHFD Model
The CDAHFD model is a widely used and well-characterized model for the evaluation of pharmacological efficacy of new treatments against liver inflammation, liver fibrosis and fatty liver diseases such as MASLD (formerly: NAFLD).
